Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 20/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 19/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235885 | 1.00 | CX3CR1 (0.60) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL212314 | 0.85 | CXCR2 (0.60) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL6624755 | 0.84 | CXCR2 (0.57) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL843148 | 0.84 | CXCR2 (0.57) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL5435212 | 0.83 | CXCR2 (0.53) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL21615424 | 0.79 | CX3CR1 (0.70) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL14490078 | 0.76 | CX3CR1 (0.75) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23528828 | 0.75 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| SCHEMBL5233299 | 0.75 | CX3CR1 (1.00) | CX3CR1CXCR2 | |
| Azd-8797 SCHEMBL30914151 | 0.75 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2022-05-24 | — | — | US | disclosed |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-11-04 | — | — | US | disclosed |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2021-09-23 | — | — | US | disclosed |
| WO-2020008064-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | KANCERA AB (SE) | 2020-01-09 | — | — | WO | disclosed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2016200939-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-8158785-B2 | 5,7-disubstituted[1.3]thiazolo [4,5-D] pyrimidin-2(3H)-amine derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | US | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1377590-B1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | ASTRAZENECA (SE) | 2007-06-21 | — | — | US | disclosed |
| US-7067657-B2 | Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | CX3CR1, CCR2, CXCR4 | CX3CR1 1/4885CXCR2 6/4885ADORA1 140/4885 |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 6/4885ADORA1 60/4885 |
| US-11339183-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20080318981-A1 | Novel Compounds 480 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 6/4885ADORA1 188/4885 |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | CX3CR1, CXCR3, CXCR5 | CX3CR1 1/4885CXCR2 15/4885ADORA1 441/4885 |
| US-20210340167-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CCR5, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 54/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 11/4885ADORA1 69/4885 |
| US-20100035899-A1 | 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 8/4885ADORA1 83/4885 |
| US-20210292349-A1 | PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | CX3CR1 1/4885CXCR2 24/4885ADORA1 21/4885 |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | CX3CR1 1/4885CXCR2 5/4885ADORA1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.